Disc Medicine, Inc.

NASDAQ:IRON

Biotechnology

Healthcare
$77.98 -0.03%

-$0.02 today

Market cap
$2.99B
Beta
2.10
P/E (TTM)
-11.2
EPS (TTM)
-$6.28
52W Low $40.00High $99.50

Volume 0.95M

Average 0.47M

IRON Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Disc Medicine, Inc.NASDAQ: IRON

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development dips below year-ago levels

Q3 FY2026 research & development of $44.08M fell 12.4% year over year, behind the +22.7% change in trailing-twelve-month research & development. Sequentially, it fell 6.1% from the prior quarter. Over 3 fiscal years it compounded at +72.2% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -12.4% toward the trailing-twelve-month pace of +22.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$44.08M-6.1% QoQ
Last fiscal yearDec 2025
$170.64M+76.5% YoY
LTMSep 2026
$183.14M+22.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.4%——
1 year+76.5%——
3-year CAGR+72.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
170.64M USD
Year-over-year change
+76.5%
4-year CAGR
+61.4%

Research & Development vs competitors

How IRON compares with its peers on the latest reported figures

  • IRON's LTM Sep 2026 research & development of $183.14M is the 3rd highest of the 6 companies compared; the peer median is $175.16M.
  • Its year-over-year change of +22.7% is the 2nd highest of 5, against a peer median of +17.5%.
  • Over three fiscal years its annual growth of +72.2% compares with a peer median of +7.1%.
IRON Competitors Peer median
Research & Development for IRON and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026$342.68M +13.3%+6.1%518.8%
DMRADamora Therapeutics, Inc.LTM Mar 2026$224.29M +4762.0%+61.0%—
IRONDisc Medicine, Inc.LTM Sep 2026$183.14M +22.7%+72.2%—
PTGXProtagonist Therapeutics, Inc.LTM Jun 2026$175.16M +21.8%+8.1%62.1%
GERNGeron CorporationLTM Mar 2026$73.59M -17.7%-8.3%37.5%
COAGHemab Therapeutics Holdings, Inc. Common StockFY2025$59.63M ———
Peer median (excluding IRON) $175.16M+17.5%+7.1%62.1%

Competitors are the stored peer set for IRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development25.17M33.44M69.26M96.67M170.64M
Selling, General & Admin5.76M14.04M21.86M33.05M65.38M
Operating Expenses30.93M47.48M91.13M129.72M236.02M
Depreciation & Amortization32K89K100K156K281K
EBITDA(33.78M)(46.74M)(76.23M)(108.27M)(207.94M)
EBITDA Margin—————
Operating Income(30.93M)(47.48M)(91.13M)(129.72M)(236.02M)
Operating Margin—————
Interest Income14K709K14.8M21.29M27.76M
Interest Expense2.16M00572K3.61M
Other Income / Expenses(5.04M)648K14.8M20.72M24.2M
Income Before Tax(35.97M)(46.83M)(76.33M)(109M)(211.82M)
Pre-Tax Margin—————
Income Tax Expense0099K355K361K
Net Income(35.97M)(46.83M)(76.43M)(109.36M)(212.18M)
Net Margin—————
EPS (Basic)(44.88)(45.05)(3.42)(3.96)(6.01)
EPS (Diluted)(44.88)(45.05)(3.42)(3.96)(6.01)
Weighted Avg Shares801.47K1.04M22.32M27.61M35.3M
Weighted Avg Shares (Diluted)801.47K1.04M22.32M27.61M35.3M

Disc Medicine, Inc.

NASDAQ:IRON

Intrinsic Alpha fair value

Locked

Current Price

$77.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.